Regenerative Medicine Sector ARMs Itself With New Advocacy Group
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies and researchers developing cell-based and tissue engineering therapies form a lobbying group to improve federal policies surrounding their efforts. The Alliance for Regenerative Medicine is ramping up to make itself heard in Washington.
You may also be interested in...
Stem Cell Therapies Walk A Risky Regulatory Road
As the most advanced stem cell therapies, known collectively these days as "regenerative medicine," edge into the clinic, much about the field remains unresolved – including basic regulatory questions and whether the therapies, which hope to restore circulation to ischemic tissue or function to damaged nerves, for example, will even work in humans.
Stem Cell Therapies Walk A Risky Regulatory Road
As the most advanced stem cell therapies, known collectively these days as "regenerative medicine," edge into the clinic, much about the field remains unresolved – including basic regulatory questions and whether the therapies, which hope to restore circulation to ischemic tissue or function to damaged nerves, for example, will even work in humans.
NIH, FDA Seeking Better Methods To Evaluate MedTech Innovations
A new collaboration between the National Institutes of Health and FDA will spur research into new tools and methodologies to evaluate the safety and efficacy of innovative medical products